Barclays PLC Sponsored ADR logo

Barclays PLC Sponsored ADR (BCS)

Market Closed
15 Oct, 08:00 PM
NYSE NYSE
$
22. 81
+0.07
+0.3078%
$
77.38B Market Cap
- P/E Ratio
0.27% Div Yield
9.81M Volume
- Eps
$ 22.74
Previous Close
Add Transaction
Day Range
22.7 23.1
Year Range
19.29 28.69
Want to track BCS and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Coinbase Slapped With Underweight Rating at Barclays: Is Crypto's Favorite Stock Heading to $140?

Coinbase Slapped With Underweight Rating at Barclays: Is Crypto's Favorite Stock Heading to $140?

Coinbase Global (NASDAQ:COIN | COIN Price Prediction) stock received an Underweight rating from Barclays on Wednesday as the firm initiated coverage with a $140 price target.

247wallst | 6 months ago
Barclays says Unilever's messy Foods exit will be worth the wait as HPC transformation takes shape

Barclays says Unilever's messy Foods exit will be worth the wait as HPC transformation takes shape

Barclays has defended Unilever PLC's (LSE:ULVR) decision to sell its Foods division to American spice giant McCormick, arguing that investor frustration with the deal's complexity is understandable but likely to fade over time. Both Unilever and McCormick shares have fallen around 8-9% since the deal was announced on 31 March, an unusually poor reception given that transactions of this kind rarely leave both parties worse off immediately.

Proactiveinvestors | 6 months ago
Barclays downgrades Future as AI and structural headwinds hit earnings forecasts

Barclays downgrades Future as AI and structural headwinds hit earnings forecasts

Barclays has downgraded Future PLC (LSE:FUTR), the digital media and magazine publisher, from 'overweight' to 'equal weight' and cut its price target by 55% to 285p from 640p, after a profit warning triggered sweeping reductions to earnings forecasts stretching out to 2028. Shares in Future were off 7% in late morning trading at 276p and have fallen 36% in the past week.

Proactiveinvestors | 6 months ago
Barclays names top 4 defensive stocks to weather global uncertainty

Barclays names top 4 defensive stocks to weather global uncertainty

As Dow Jones slides into the “correction territory” and the benchmark S&P 500 index logs its fifth consecutive week of losses, investors are increasingly desperate for a port in the storm. According to Barclays' senior analyst Andrew Ferremi, the market has shifted into a new, volatile era where geopolitical tensions, oil price spikes, and AI-driven disruption are “no longer episodic shocks but persistent features of the investment landscape.

Invezz | 6 months ago
Bullish On Barclays Again, As It Stands Out Among Europe's Global Diversified Banks

Bullish On Barclays Again, As It Stands Out Among Europe's Global Diversified Banks

Barclays is reaffirmed as a buy, standing out for strong fundamentals, performance vs. similar banks, attractive valuation, and upside forecasts despite macro headwinds. BCS demonstrated robust top-line growth, peer-leading margins, and global business diversification, with notable momentum in investment banking and US consumer lending. Balance sheet risk is balanced by strong credit ratings and stable asset quality, though high leverage and private credit exposure warrant monitoring.

Seekingalpha | 6 months ago
Phathom Pharmaceuticals Upgraded by Barclays to Overweight With $18 Target

Phathom Pharmaceuticals Upgraded by Barclays to Overweight With $18 Target

Barclays analyst Jenna Davidner upgraded Phathom Pharmaceuticals (NASDAQ:PHAT) to Overweight from Equal Weight on Friday, raising her price target to $18 from $16.

247wallst | 6 months ago
U.S. administration wants a quick deal with Iran: Barclays

U.S. administration wants a quick deal with Iran: Barclays

Mitul Kotecha of Barclays sees no signs of an 'obvious off-ramp' between the U.S. and Iran despite the discussions. He says major central banks are turning hawkish, and sees 'pain' for countries who are energy importers.

Youtube | 6 months ago
Why Barclays Thinks Ionis Is Headed for a 45% Surge From $73 to $106

Why Barclays Thinks Ionis Is Headed for a 45% Surge From $73 to $106

Ionis Pharmaceuticals (NASDAQ:IONS) has delivered a remarkable 137.52% gain over the past year, though the stock has pulled back 6.12% year-to-date and sits 7.20% below its one-month high, currently trading near $72.70.

247wallst | 6 months ago
Barclays sees 13–14 million bpd oil supply loss from prolonged Hormuz disruption

Barclays sees 13–14 million bpd oil supply loss from prolonged Hormuz disruption

Barclays said on Thursday that a prolonged closure of the Strait of Hormuz would likely lead to a 13-14 million barrels per day supply loss, ​noting that while the scale of the disruption is immense, so ‌is the uncertainty around its duration.

Reuters | 6 months ago
Molson Coors Could Drop Another 3% as Barclays Slashes Target to $40 With Underweight Rating

Molson Coors Could Drop Another 3% as Barclays Slashes Target to $40 With Underweight Rating

Molson Coors (NYSE:TAP) has been under sustained pressure heading into 2026.

247wallst | 6 months ago
Carnival Stock Cut by Barclays and Truist, but This Wall Street Pro Still Sees Upside

Carnival Stock Cut by Barclays and Truist, but This Wall Street Pro Still Sees Upside

Carnival Corporation (NYSE:CCL) is heading into its March 27 Q1 2026 earnings report with two Wall Street firms moving in the same direction on price targets but landing in very different places on conviction.

247wallst | 6 months ago
Barclays PLC (BCS) Presents at European Financials Conference 2026 Transcript

Barclays PLC (BCS) Presents at European Financials Conference 2026 Transcript

Barclays PLC (BCS) Presents at European Financials Conference 2026 Transcript

Seekingalpha | 7 months ago
Loading...
Load More